Study to ONO-4538 in Patients With Rhabdoid Tumor
Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors
Rhabdoid Tumor
DRUG: ONO-4538
Objective response rate (ORR), up to 4.5 years
Objective response rate (ORR) (site investigator assesment), up to 4.5 years|Overall survival (OS), up to 4.5 years|Progression free survival (PFS), up to 4.5 years|Disease control rate (DCR), up to 4.5 years|Time to response (TTR), up to 4.5 years|Best overall response (BOR), up to 4.5 years|Percent change from baseline in the sum of diameters of target lesions, up to 4.5 years|Best reduction percent change from baseline in the sum of diameters of target lesions, up to 4.5 years|Incidence of Adverse Events [Safety], Up to 30 days after the last dose
Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors